How is phenylalanine hydroxylase deficiency (phenylketonuria) diagnosed and managed?

Phenylalanine Hydroxylase Deficiency: Diagnosis and Management

Diagnosis

Phenylalanine hydroxylase (PAH) deficiency is diagnosed through newborn screening with dried blood spot testing, followed by confirmatory quantitative plasma amino acids, pterin metabolism analysis, and PAH genotyping. 1

Diagnostic Algorithm

After a positive newborn screen showing elevated phenylalanine:

• Obtain quantitative blood amino acids measuring phenylalanine (Phe), Phe:Tyrosine ratio, and complete amino acid profile 1
• Analyze blood and/or urine pterin metabolism to exclude tetrahydrobiopterin (BH4) synthesis or recycling defects, which present differently and require distinct treatment 1
• Perform PAH genotyping at birth to confirm diagnosis and guide therapy planning 1

The 2025 ACMG guidelines strongly emphasize that genetic testing is now recommended at birth, representing an evolution from the 2014 guidelines where this was less emphasized.

Management

Lifelong treatment maintaining blood phenylalanine ≤360 μmol/L (using plasma or whole blood) is strongly recommended for all patients with untreated Phe levels >360 μmol/L to optimize intellectual outcomes and prevent teratogenicity. 1

This represents the most critical evidence-based recommendation from the 2025 ACMG guidelines, now supported by strong evidence showing that individuals maintaining lifetime Phe ≤360 μmol/L have higher IQ scores.

Treatment Modalities

1. Dietary Management (First-Line)

• Phenylalanine-restricted diet avoiding high-protein foods (meat, fish, eggs, nuts)
• Phenylalanine-free medical formulas to provide adequate protein and nutrition
• Target Phe levels: 120-360 μmol/L throughout life 1

2. Sapropterin (Pharmacologic Adjunct)

Before initiating routine sapropterin therapy, conduct a responsiveness test at 20 mg/kg daily dose—testing at lower doses underestimates response rates. 2

Sapropterin Responsiveness Testing Protocol:

• Obtain baseline blood Phe level on day medication starts
• Administer sapropterin 20 mg/kg once daily
• Measure Phe levels at 24 hours, 1 week, 2 weeks, and sometimes 3-4 weeks
• A ≥30% reduction in blood Phe constitutes a positive response 2
• Most responders show rapid decline, but occasionally 2-4 weeks delay occurs 2

Critical caveat: Patients with baseline Phe at the lower treatment range (≤180 μmol/L) rarely show significant decline even if sapropterin-responsive. In these patients, responsiveness must be determined by adding dietary Phe stepwise to assess if increased Phe tolerance is achieved while maintaining low blood Phe levels 2.

Justification for continuing therapy includes:

• ≥30% Phe reduction
• Improvement in neuropsychiatric symptoms
• Increased Phe tolerance (allowing 2-3 fold increase in dietary protein intake) 2

The major benefit is improved quality of life through increased dietary protein tolerance in responsive patients 2.

3. Large Neutral Amino Acids (LNAA)

• Limited to older patients (adolescents and adults)
• Contraindicated in pregnancy as monotherapy—does not lower Phe sufficiently for safe fetal development 2
• Not recommended during pregnancy per 2025 guidelines 1
• Demonstrated ~40% Phe reduction in single trial, but larger trials needed 2

4. Emerging Therapies

PEG-PAL (pegvaliase): Polyethylene glycol-conjugated phenylalanine ammonia lyase entered phase III trials in 2013, effective in lowering blood Phe even on unrestricted diet, administered as daily subcutaneous injection 2. This therapy works independently of PAH enzyme and is theoretically effective in all patients.

Special Populations

Maternal PAH Deficiency

Achieving Phe ≤360 μmol/L before conception is strongly recommended to prevent pregnancy complications and negative offspring outcomes. 1

The evidence is now strong that:

• Elevated maternal Phe during pregnancy causes microcephaly (5-18% if control achieved by 10 weeks, 67% if not controlled by 30 weeks)
• Congenital heart disease risk increases 8-12% with Phe >600 μmol/L during early gestation (before 8-10 weeks when fetal heart develops) 2
• Intrauterine growth retardation risk increases with later onset of Phe control 2

Management during pregnancy:

• Routine prenatal care supplemented by close fetal growth monitoring
• Assessment for fetal congenital heart disease by high-risk obstetrics group 1
• LNAA contraindicated 1

Previously Untreated or Late-Treated Patients

Patients who discontinued therapy will likely experience neuropsychological improvements with reinstitution of therapy. 2

For patients with late-treated PAH deficiency and severe cognitive impairment:

• Trial of treatment justified even if cognitive improvement unlikely
• Anecdotal evidence suggests improvements in behavior, psychiatric symptoms, and seizure control 2
• Conduct sapropterin response test on unrestricted diet if desired
• If dietary intervention preferred, make stepwise dietary changes until Phe controlled
• Treat for minimum 6 months with careful monitoring before considering discontinuation 2

Monitoring Requirements

• Age-specific neuropsychiatric and cognitive testing necessary to assess clinical needs 1
• Regular blood Phe monitoring throughout life
• Appropriate intellectual and mental health assessments as important component of care 1

Key Pitfalls to Avoid

1. Do not test sapropterin responsiveness at doses <20 mg/kg—this underestimates response rate 2
2. Do not use LNAA as monotherapy in pregnancy—insufficient Phe lowering for fetal safety 2, 1
3. Do not assume genotype predicts sapropterin response—formal testing required 2
4. Do not discontinue treatment in adulthood—lifelong therapy essential for optimal outcomes 1
5. Do not delay preconception Phe control in women—teratogenic effects occur early in pregnancy 1

Treatment Philosophy

The primary goal is lowering blood Phe to ≤360 μmol/L using any combination of therapies (dietary, pharmacologic, or both) that achieves this target without negative consequences. 2 Secondary goals include improved dietary Phe tolerance, symptom amelioration, and improved quality of life 2.

The 2025 ACMG guidelines represent a significant strengthening of evidence compared to 2014, with key recommendations now strongly supported rather than based on expert consensus alone.